Retagliptin

Metabolites - Retagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor developed for the treatment of type 2 diabetes by increasing incretin levels to improve insulin secretion and blood glucose control. Reference standards of Retagliptin API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.

No Data Found